Universal Early Parenting Programmes: Unraveling the Cost-Effectiveness

By Thanusha Pillay

June 14, 2024

Introduction

Inadequate care during infancy can have lasting repercussions, impacting various sectors and necessitating increased expenditure on health, social, educational, and judicial services. Positive parenting is a growing public health priority and parenting programmes have been shown to be valuable and effective. Universal Early Parenting Programmes are increasingly popular for enhancing positive parenting practices and addressing skill and attitude gaps across diverse populations.

The Efficacy of Universal Parenting Interventions

Research underscores the potential of early parenting programmes in enhancing parental knowledge and skills. While short-term benefits are evident, long-term impacts of universal interventions on parenting and child development are not thoroughly investigated.

Exploring the Parent and Infant Programme

This study looked into the cost and cost-effectiveness of the Parent and Infant (PIN) programme, a universal intervention targeting parental attitudes and responsive parenting strategies during the early years. The researchers piloted the program in two sites in the Republic of Ireland and compared it to services as usual (SAU). They assessed the cost-effectiveness of the program from an Irish health and social care perspective over 24 months. The primary outcome measure was the Parenting Sense of Competence Scale (PSOC), and by focusing on parent satisfaction this analysis sheds light on the programme’s efficacy.

Fig. 1

Figure 1. Overview of the PIN programme adapted from Hickey et al., 2020

Results and Cost Analysis

With 163 parent-infant dyads analysed (86 in the programme, 77 control), the PIN programme demonstrated a mean cost of €647 per dyad. The PIN service achieved a mean incremental cost-effectiveness of €614 per PSOC unit gained. At a willingness-to-pay of €1,000 per one unit change in the PSOC, the PIN programme proved cost-effective compared to SAU. The PIN programme showcased positive impacts on parental competence and was viable at a reasonable threshold.

Discussion and Implications

While the study highlights the success of the PIN programme, challenges in evaluating the cost-effectiveness of early interventions persist. The complexities of assessing outcomes in children, coupled with the need for a broader evaluative framework, highlight the necessity for further research and nuanced approaches to appraise the effectiveness of such programmes.

Conclusion

The study emphasise the potential of Universal Early Parenting Programmes in enhancing parental competence and fostering positive childhood behavioural outcomes. Navigating cost-effectiveness challenges, the field requires more research and robust trials to inform policy decisions and resource allocation effectively.

Reference url

Recent Posts

BioNTech BMS collaboration
   

BioNTech BMS Collaboration: Pioneering Advances in Solid Tumor Treatment with BNT327

🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?

Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.

Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!

#SyenzaNews #oncology #drugdevelopment #MarketAccess

Pluvicto prostate cancer trial
        

Pluvicto Prostate Cancer Trial: Phase III Results

🔍 Have you heard about the latest breakthrough in prostate cancer treatment?

Novartis’s Pluvicto™ has shown significant clinical benefits in earlier-stage prostate cancer, highlighting its potential to transform treatment paradigms for patients with metastatic hormone-sensitive prostate cancer. With promising data on radiographic progression-free survival, the implications for healthcare systems are profound, pushing us toward more effective and targeted therapies for this pressing health challenge.

Dive into the full article to explore how Pluvicto™ is shifting the landscape of prostate cancer management!

#SyenzaNews #oncology #HealthcareInnovation

Novo Nordisk performance
      

Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share

🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.

A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.

#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.